Vantage logo

Finding the next Vertex

Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.

Vantage logo

CD47 is worth $4.9bn to Gilead

A $4.9bn buyout of Forty Seven means that Gilead remains focused on oncology, though cell therapy bulls are none the wiser.